Delving into the Latest Updates on Interferon alpha-2a(LG Life Sciences Ltd.) with Synapse

Overview

Basic Info

Drug Type

Interferons

Synonyms-

Target

IFNα2

Mechanism

IFNα2 stimulants(Interferon alpha-2 stimulants)

Therapeutic Areas

Infectious DiseasesDigestive System Disorders

Active Indication-

Inactive Indication

Hepatitis C

Originator Organization

LG Life Sciences Ltd.

Active Organization-

Inactive Organization

LG Life Sciences Ltd.

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

Immunotherapies using interferons and/or interleukins are currently the treatment of choice for metastatic renal cell carcinoma (RCC). Bone metastases and non-resectable local recurrence are negative predictors for successful immunotherapy and signs of poor prognosis. The present study was designed to evaluate the effectiveness of combined immunochemotherapy (ICT) and radiation therapy (RT) for bone metastases or local recurrence from RCC in a prospective fashion. From September 1997 to September 1999, 20 patients with progressive RCC were treated with a combination of RT and ICT [s.c. interleukin-2a (IL-2), s.c. interferon alpha (IFN-alpha) and i.v. 5-fluorouracil]. RT started in week 2 of ICT. The radiation field was limited to the symptomatic bone metastases (15 patients) or the local recurrence (five patients). The total dosages of the RT ranged between 45 and 50 Gy, administered in fractions of from 1.8 to 2 Gy daily. In case of objective response or stable disease, the patients received up to two further ICT courses. All patients had good pain relief. Three out of 20 achieved complete remission, three had a partial remission, nine were stable and five patients had progressive disease under the combined treatment. Median survival was 21 months, mean survival 24 months (range: 5-59 months). The side effects of the combined treatment are in the same range as with ICT alone (World Health Organisation grade 2 and 3). Of 20 patients, 19 had their pain medication reduced after treatment. The combination of ICT and RT is feasible. There is remarkable pain relief. Our data suggest that the combination of immunochemotherapy and radiation therapy may induce a synergistic antitumor effect for the treatment of bone metastases or local recurrence from RCC compared to data from the literature for ICT or RT alone.

16 Sep 2001·Orvosi hetilapQ4 · MEDICINE

[Interferon-alpha and PUVA therapy for mycosis fungoides].

Q4 · MEDICINE

Article

Author: Hársing, J ; Horváth, A ; Hídvégi, B ; Désaknai, M ; Kovács, J ; Berecz, M ; Somlai, B ; Marschalkó, M

14 patients suffering from early stage mycosis fungoides were treated with interferon alpha 2-a and PUVA/1 patient in stage I a, 3 patients in stage I b, 4 patients in stage II a and 6 patients in stage II b/during 3-21 months time course. Interferon alpha 2-a was administered 3 times a week, in escalating dose from 3 MU to 9 MU, determining the individual maximal tolerated dose. All of the patients responded well to the treatment. Partial remission was observed after 4-13 weeks of treatment. Total remission developed in 8 cases, after 8 weeks- 9 months of the treatment. Side effects occurred frequently: weight loss, pain, fever, fatigue, leucopenia, thrombopenia, liver enzyme elevation. Because of the side effects the dose of the interferon was reduced individually, the dose reduction did not cause relapse.

100 Deals associated with Interferon alpha-2a(LG Life Sciences Ltd.)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatitis C	Phase 2	-	LG Life Sciences Ltd.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EHA2022	Not Applicable	Anemia, Dyserythropoietic, Congenital	-	Interferon-Alpha-2a	(urzcwpvaft) = nefvnqcoqa ieoirddnyw (kjwqscifos )	-	10 Jun 2022
ASCO2005	Phase 2	Metastatic Renal Cell Carcinoma	37	TG4010 alone	(bdoffoqpnk) = hqurkmpmit ozqkcpnnjm (cmcxepqmua, 62–89) View more	-	01 Jun 2005
ASCO2005	Phase 2	Metastatic Renal Cell Carcinoma	37	TG4010 + Interferon alpha-2a (INF) + Interleukin 2 (IL2)	(bdoffoqpnk) = grtwwupubj ozqkcpnnjm (cmcxepqmua, 40–77) View more	-	01 Jun 2005